RECMA Bio
Robotic Enabled Cellular Matrix Application
Health Tech & Life Sciences
Non Active, Oct 2024 ceased to operate
Company Overview
Snapshot
Founded in October 2022, RECMA Bio operates with 1–10 employees. The company is currently in a non-active status, having ceased operations in October 2024.
Business overview
RECMA Bio is focused on addressing the unmet need in tissue regeneration by combining biomaterial sciences, tissue engineering, 3D bioprinting, and robotics. The company is developing a robotic system for in-situ bioprinting, designed to leverage the body's natural regenerative and healing capabilities. Operating within the Health Tech & Life Sciences sector, RECMA Bio serves the medical devices and biomaterials & tissue engineering markets.
Log in to access full profile ›Company Intelligence Q&A
- What is RECMA Bio's primary focus?
- RECMA Bio's primary focus is on resolving challenging unmet needs in medicine, specifically in tissue regeneration, by developing advanced robotic systems.
- When was RECMA Bio founded?
- RECMA Bio was founded in October 2022.
- What technologies does RECMA Bio combine in its approach?
- RECMA Bio combines biomaterial sciences, tissue engineering, 3D bioprinting, and robotics to develop its in-situ bioprinting system.
- What is the current operational status of RECMA Bio?
- RECMA Bio is currently non-active, having ceased operations in October 2024.
- In which sector does RECMA Bio primarily operate?
- RECMA Bio primarily operates in the Health Tech & Life Sciences sector, with a focus on medical devices and biomaterials & tissue engineering.